"Sterilization of TB disease in
|
|
- Scot Foster
- 6 years ago
- Views:
Transcription
1 11/1/1 "Sterilization of TB disease in mice " Jacques Grosset Pharmacodynamics of daily rifapentine and rifampin in mice Free rifam mycin Concentrati ion/mic 1 1 Rifapentine (1mg/kg) Free rifam mycin Concentrati ion/mic 1 1 Rifampin (1mg/kg) Center for TB Research Johns Hopkins University Time (hrs) Time (hrs) Rifapentine provides greater rifamycin exposure than does rifampin at the same given dose Rosenthal et al. PLoS Medicine, 7 Log 1 cfu in lungs Our goal Persisters INH + SM INH + RIF INH + RIF + PZA months Chemotherapy of TB: Activity of INH+SM, INH+RIF, or INH+RIF+PZA in mice (and in humans) against persisters Bactericidal activity of daily R 1 HZ & P 1 HZ 7 R 1 HZ P 1HZ Treatment duration (weeks) Conclusion:, To reach the culture ve state, it takes 1 weeks with P 1 HZ and 1 to weeks with R 1 HZ per Lung Log 1 CFU Rifapentine (P) Rifapentine (P) is a long lived rifamycin derivative developed for once weekly administration (Bock, ) Rifapentine offers potential for improved activity because of its superior PK/PD profile: Drug Half life (h) MIC 9 (μg/ml) C max /MIC 9 AUC /MIC 9 Rifampicin (1 mg/kg) Rifapentine (1 mg/kg) P may be safely administered more frequently and at higher doses than mg once a week Sterilizing efficacy of rifapentine (P) containing regimens Regimens Culture negative Relapse after treatment for at weeks at 1 weeks 1 weeks 1 weeks R 1 HZ /7 / (%) / (%) 1%! 1%! P 1 HZ /7 1/ (%) / (1%) /1 (% 13%) /1 (%) Questions: Does the culture negative state obtained in mice treated with PHZ correspond to a sterile state? Have we really killed all persisters? Absence of relapse may indicate the few remaining persisters are contained by specific immunity. Thus. 1
2 11/1/1 Data on the sterile state achieved by drug therapy McCune et al., 19: After culture conversion induced by INH + high dose PZA, the relapse rate was % without any intervention and 1% after cortisone 1 mg ( mg/kg) daily for days Grumbach et al., 197: After INH + RIF for 1 months, the relapse rate was % without any intervention but % after cortisone. mg ( mg/kg) daily for months Lung CFU counts after treatment for 1 month with P 1 HZ/1PH CFU/Lung Log 1 1 Weeks post treatment initiation : 3.93 :. p =. Basic study design Aim: Determine whether intensive treatment with daily (/7) P 1 HZ/PH leads to true sterilization Tests: Athymic nude (nu/nu) mice given PHZ/PH for 3,, 9, and 1 months and kept without treatment for 3 months to reveal sterile state Normal mice () treated as above but injected with cortisone (mg/kg, /7, for wks) upon treatment completion Normal mice () treated as above but without receiving cortisone upon treatment completion Controls: Exactly the same as above but treated with RHZ/RH Lung CFU counts after treatment for months with P 1 HZ/1PH CFU/Lung Log 1 1 Weeks post treatment initiation :.9 :.3 p =.17 Lung CFU counts on treatment initiation Lung CFU counts after treatment for 3 months with P 1 HZ/1PH All controls dead by Day All controls dead by Day CFU/Lung Log 1 CFU/Lung Log 1 1 Weeks post treatment initiation 1 Weeks post treatment initiation one day after infection :. :. on treatment initiation : 7. : 7.3 Conclusion: identical active growth of Mtb in normal and nude mice Conclusion: Response is significantly slower in nude mice than in normal mice but all mice were culture negative by 3 months
3 11/1/1 Relapse rate after treatment for 3 months with P 1 HZ/1PH Group of mice Cortisone Relapse rate 3 months later No Cortisone /1 (%) Relapse rate after treatment for /9/1 months with P 1 HZ/PH given d/week Group of mice Cortisone /1 Relapse rate 3 months later No Cortisone /1 /1 Conclusions: 1. After months of PHZ/PH given days a week, not a single nude mouse relapsed, indicating the spectacular sterilizing activity of rifapentine. The time to lung sterilization with PHZ/PH is therefore between 3 and months 3. A new experiment is in progress to determine the minimum time to sterilization of all mice with the P containing regimen Relapse rate after treatment for 3 months with P 1 HZ/1PH Group of mice Cortisone /1 (13%) * Relapse rate 3 months later No Cortisone /1 (%) *By error these mice received only. mg (mg/kg) daily cortisone instead of 1 mg (mg/kg) What about the control mice treated with RHZ/RH? In all mice, and, treated d/wk with R 1 HZ/RH, the cultures were still positive at the 3 month time point when they were all culture negative in mice treated with P 1 HZ/PH. This again emphasizes the potency of P over R. Let s see the details Relapse rate after treatment for 3 months with P 1 HZ/1PH Results during the first 3 months of treatment RHZ Group of mice Cortisone /1 (13%) Relapse rate 3 months later No Cortisone /1 (%) 11/1 (73%) Conclusions: 1. As seen previously, normal mice did not relapse spontaneously.only /1 normal mice given cortisone for 1 month relapsed (but..) 3.Only 11/1 nude mice relapsed! Log 1 CFU/Lung L - Log 1 CFU counts: one day after infection BALB/C:. :. 1 Weeks post treatment on treatment initiation BALB/C: 7. : 7.3 3
4 11/1/1 Rifampicin Conc. ( g/ml) Pyrazinamide Conc. ( g/ml) Rifampicin (1 mg/kg) 1 1 Time (hours) Pyrazinamide (1 mg/kg) 1 1 Time (hours) Drug (mg/kg) Isoniazid Conc. ( g/ml) 1 Isoniazid (1 mg/kg) Time (hours) Mice C max AUC - (mg.h/l) Humans C max AUC - (mg.h/l) RIF 1 1. ± INH rapid - - Cmax. ±. AUC. R1-1. ± 3.3 ± slow H1.7 ± INH 1 ± PZA -3 - Z ± ±.9 ± 11 PZA ± What have we done? A new experiment in which nu/nu and Balb/C mice were treated for 3 months with: versus 7 days a week RHZ/RH versus RHZE*/RH *ethambutol 1mg/kg Results after months of treatment in nude mice treated with RHZ/RH, RHZ times weekly Log 1 CFU/Lung INH-R mutants * INH-R** RIF-S 1 1 Weeks post treatment * Between 1% to % CFU resistant to. µg/ml of INH ** For all mice, ~ 1% CFU resistant to. & 1 µg/ml of INH 1. Is 7 day/wk treatment able to prevent selection of INH resistant mutants? (RHZ/RH days a week versus 7 days a week in Balb/C and Nu/nu mice) Strain of mice Rhythm of treatment D 13 D M1 M M3 Resist to INH Balb/C untreated Dead by D / /1 7/7.3.. /1 Nu/nu Untreated. 7.3 Dead by D / /1 7/ /1 Conclusions: 1. 7/7 is more active than /7 treatment but. Treatment with RHZ/RH given 7/7 does not protect better against INH resistance than /7 in nu/nu mice Results after months (3wks) of treatment in mice treated with RHZ/RH, times weekly. Is the addition of ethambutol (E) able to prevent the selection of INH resistant mutants? (RHZE/RH 7/7 versus /7) ** * Strain of mice Rhythm of treatment D 13 D M1 M M3 Resist to INH Balb/C untreated Dead by D / /1 7/ /1 Nu/nu Untreated. 7.3 Dead by D / /1 7/ /1 *All INH R and RIF S. But mice [ at wk 3 & at wk 3 out of 7 (1.%)] were culture negative, indicating that the treatment was active when there was no selection of INH R mutants in mice. ** Mock multiplication in untreated nude mice Conclusion: The addition of E protected against selection of INH resistant mutants when RHZE/RH was given /7 or 7/7
5 11/1/1 3. Is 7 days a week more potent than days a week? (RHZE/RH d/wk versus 7d/wk in Balb/C and Nu/nu mice) Strain of mice Rhythm of treatment D 13 D M1 M M3 Resist to H Balb/C untreated Dead by D / /1 7/ /1 Nu/nu Untreated. 7.3 Dead by D / /1 7/ /1 Conclusions: 1. In both mouse strains 7/7 is. to 1. log 1 more bactericidal than /7. The response to /7 or 7/7 is 1 to log 1 better in Balb/C than in nu/nu Conclusion: 1. the facts P 1 HZ/PH given /7 sterilizes TB disease in nude mice within 3 to months Nu/nu mice treated with daily RHZ/RH selected INH resistant mutants and not RIF resistant mutants The addition of EMB (E) during the -month initial phase prevented the selection of INH resistant mutants 7/7 treatment is on average 1 to 1. log 1 more bactericidal than /7, both in nu/nu and Balb/C mice The bactericidal activity of RHZE/RH in nu/nu mice is reduced by 1 to log 1 compared to Balb/C Log 1 CFU co ounts in Lungs 9 Treatment initiation RHZE RH Balb/C-Untreated Balb/C-RHZE /7 Balb/C-RHZE 7/7 Nu-Untreated Nu-RHZE /7 Nu-RHZE 7/7 Weeks Conclusion:. Speculations One can predict a spectacular efficacy of the P 1 HZE/PH treatment in humans (TBTC study 9) In immune-deficient hosts, bacilli are not contained by the host immunity and can re-grow as soon as they are no more under the control of antibiotics: - Should immune-deficient patients with TB be preferably treated daily and seven days a week (7/7)? The inability of daily R (a sterilizing but poorly bactericidal drug) to prevent the selection of H (a potent bactericidal drug) resistant mutants in the absence of a specific immune response is amazing. Perhaps should we increase dose/rhythm of R? The ability of Ethambutol (a bacteriostatic drug), in combination with RHZ, to prevent the selection of H resistant mutants in nude mice is amazing. Does ethambutol substitute for the immune containment? 1 Lung CFU counts in Balb/C (B) and nude (Nu) mice treated /7 (---) vs 7/7 ( ) with RHZE. Is the addition of ethambutol increasing the bacteridal actity? Strain of mice Balb/C Drug Log 1 lung CHU at following time points regimens D M1 M M3 untreated 7.7 /7 ZHZ/RH /7 RHZE/RH Acknowledgements We acknowledge the support of all TB center members and of NIAID (Contract # N1-AI-7) We thank Sanofi Aventis for providing rifapentine and I thank you for your attention 7/7 RHZ/RH.3.. 7/7 RHZE/RH Conclusion: The addition of ethambutol does not increase bactericidal activity
6
7 Tuberculosis and HIV Co-infection November 3, 1 Timothy R. Sterling, M.D. Vanderbilt University School of Medicine Smear-negative TB in HIV + Persons Atypical CXR presentation Risk is increased in HIV + persons Proportion of TB in HIV + persons that is smear-negative pulmonary: -1% 1 institution-based studies May be an under-estimate Risk of death increased Compared to HIV-negative smear-negative TB patients immunosuppression Compared to HIV-positive smear + TB patients delay in diagnosis Getahun H. Lancet 7;39:-9. Issues in TB/HIV Clinical Presentation of TB in HIV + Persons Sub-clinical TB, atypical presentation Immune reconstitution Treatment of TB/HIV Optimal duration of therapy; relapse risk Development of drug-resistant TB Acquired rifamycin resistance TB drug levels in HIV+ patients Drug-drug interactions Algorithm for TB Screening in HIV+ Persons 1,7 HIV+ persons in Cambodia, Thailand, and Vietnam TB diagnosed in 7 (1%) Presence of cough for > -3 weeks during the preceding weeks: -33% sensitive -% specific Presence of at least one (cough any duration, fever any duration, night sweats for > 3 weeks in preceding wks) 93% sensitive 3% specific 97% negative predictive value Cain KP. N Engl J Med 1;3:77-1. Diagnosis of TB in HIV+ Persons 1,199 patients who reported > 1 of these symptoms Tanzania 1/93 (1%) of HIV+ subjects (CD > ) screened for TB vaccine trial had active TB 1 (71%): clinical TB Symptoms or abnormal CXR (9%): sub-clinical TB +AFB smear/cx but no symptoms and normal CXR more cases subsequently identified» Of the 1, 7 identified only by + culture Mtei L. Clin Infect Dis ;:1-7 South Africa 17 HIV+ persons evaluated with AFB smear and culture 7 already on TB Rx previously undiagnosed smear + TB, smear-neg/culture + TB % had previously undiagnosed TB. Symptom screen not useful Wood R. AJRCCM 7;17:7-93 Supports use of CXR, sputum culture to rule out TB Generally not done in developing world /1199 = % /1199 = % 13/1199 = 1% Cain KP. N Engl J Med 1;3:77-1. Of 9 patients without any of the 3 screening symptoms, 1 (3%) had TB 1
8 Case Presentation Development of TB after HAART Initiation Schematic representation of the different forms of TB-associated IRIS and ART-associated TB y.o. HIV+ male with diarrhea, fevers, 3 lb weight loss. No cough or SOB. CXR negative. C CD = 3 3 HIV-1 RNA: 9, 9, TDF/FTC/lopinavir/ritonavir initiated days later: presents with cough, fever. CXR: RUL cavitary infiltrate Culture-confirmed pulmonary TB Meintjes G et al for the International Network for the Study of HIVassociated IRIS. Lancet Infect Dis ;:1-3. Manabe Y. J Infect Dis. 9 Feb 1;199(3):37-. Immune Reconstitution Inflammatory Syndrome Among Persons Known to Have TB Clinical Manifestations Prior to HAART days after starting HAART Constitutional: fever, weight loss Pulmonary: cough, increased infiltrates Extrapulmonary: Lymphatic: increased cervical, intra-thoracic, intraabdominal adenopathy Serositis: pleural, pericardial effusions CNS: expanding tuberculomas Other: soft tissue, bone abscesses, skin, +PPD Smear-positive, culture-negative Manabe Y. J Infect Dis. 9 Feb 1;199(3):37-. Schematic representation of the different forms of TB-associated IRIS and ART-associated TB Previously undiagnosed prevalent TB Newly-acquired TB Meintjes G. Lancet Infect Dis. Lawn SD. AJRCCM. Manabe Y. J Infect Dis 9. Progression of sub-clinical TB present before ART (reactivation) A sub-set have IRIS Meintjes G. Lancet Infect Dis ;:1-3.
9 Effect of HAART on TB risk Overall, immune reconstitution due to HAART decreases, not increases, TB risk Unmasking of sub-clinical TB due to immune reconstitution on HAART can occur Implications for ART implementation in settings with high TB incidence Incomplete long-term immune restoration TB risk higher than in HIV-seronegative persons Lawn SD. AIDS ;19: Lawn SD AJRCCM ;177:-. Manabe Y JID 9. Treatment of TB for Months HIV-seropositive vs. HIV-seronegative Location Relapse HIV+ Relapse HIV- Reference Zaire 9%.3% Perriens NEJM 199 Cote d Ivoire 3% 3% Kassim AIDS 199 Haiti.%.7% Chaisson AJRCCM 199 U.S. 3.9% El-Sadr CID 199 South Africa % % Connolly AIDS 1999 U.S..% 3% Sterling AIDS 1999 Recurrent TB After Treatment Completion Relapse vs. Reinfection Relapse: disease with the same M. tb strain as the first episode Related to treatment duration, effectiveness Reinfection: disease with new strain of M. tb Related to TB prevalence in area Optimal Duration of TB Treatment Regardless of HIV status Site of Disease Pulmonary Bone/joint CNS/meningeal Other extrpulmonary Duration months* -9 months 9-1 months months *Extend to 9 months if cavitary and culture + at months American Thoracic Society, Centers for Disease Control, IDSA. Treatment of Tuberculosis. AJRCCM 3;17:3- Recurrent TB Relapse vs. Reinfection In TB-endemic areas, recurrent TB after completion of therapy more likely due to exogenous reinfection than relapse van Rie, et al. N Engl J Med. 1999;31:117. Narayanan S. J Infect Dis. 1 Mar 1;1(): HIV+ TB patients have higher risk of recurrent TB than HIV-negative TB patients, but this is due to reinfection, not relapse Sonnenberg P, et al. Lancet 1;3:17 Glynn JR. J Infect Dis. 1 Mar 1;1():7-11.Crampin AC. AIDS 1;:17. Treatment of TB in HIV+ Persons Relapse Rates months Relapse rate = % (range: 3 9%) Perriens NEJM 199 El-Sadr CID 1 Sterling AIDS 1999 Korenromp CID 3 Fitzgerald Lancet Nettles CID Nahid AJRCCM 7 9 months Relapse rate = % (range 1 3%) Pulido Arch Intern Med 1997 Driver CID 1 3
10 Treatment of TB/HIV Systematic Review and Meta-analysis randomized trials, 1 cohort studies Trend toward higher relapse rate if: rifamycins i used for months vs. > months antiretroviral therapy not used Thrice-weekly therapy in initial phase associated with higher failure and relapse rates than daily therapy Pharmacokinetics of INH + Rifabutin Acquired Rifamycin Resistance Included 1/13 Study 3 patients;7/ with ARR ARR No ARR P Rifabutin AUC 3.3 g*ml/hr. g*ml/hr. adjusted for CD 3... Isoniazid AUC... adjusted-rbt AUC. Khan FA. Clin Infect Dis 1;: Weiner M. Clin Infect Dis ;:11-91 Outcome vs. 9 Months India; Thrice-weekly TB Rx; No ART months N=17 9 months N=1 P-value Favorable 3% 7% NS response Bacteriologic 1% 7% <. recurrence All recurrence 19% 13% NS Death-3 months 3% 3% NS Median CD: 1 Median HIV-1 RNA: 1, copies/ml All 19 patients with Rx failure: acquired rifamycin resistance No difference in ARR by treatment arm Swaminathan S. AJRCCM 1;11:73-1. Rifabutin Isoniazid Weiner M. Clin Infect Dis ;:11-91 Acquired Rifamycin Resistance TB Trials Consortium Study 3 Isoniazid + rifabutin twice-weekly in continuation phase 19 patients enrolled 3 treatment failures + relapses; 9/19 =.3% /9 (9%) acquired rifamycin resistance Risk factors for ARR: ARR No ARR P n= n=11 Median CD 99.1 ART in 1 st mos. of TB Rx 1% %. Recommendations for Treatment of TB in HIV-Infected Patients TB/HIV patients with CD < 1 should not receive once- or twice- weekly therapy Daily therapy during induction Daily or thrice-weekly therapy during continuation Burman W. Am J Respir Crit Care Med ;173:3-. MMWR ;1:1-
11 Prevalence of Low Drug Levels During TB Treatment TB patients in Botswana DOT HIV-infected and -uninfected Low TB drug levels common Drug % with low C max INH 37 RIF EMB 39 PZA Chideya S. Clin Infect Dis 9;:1-9. Chideya S. Clin Infect Dis 9;:1-9. Treatment of TB/HIV Possible Uses of Rifampin ( mg) RIF + efavirenz (consider mg) RIF + ritonavir mg bid RIF + lopinavir ( mg) + ritonavir ( mg) Concern re: hepatotoxicity in adults (OK if < 3 years old) Above regimens must also include NRTIs Do not use rifampin with other PIs, even if the PI is given with ritonavir Chideya S. Clin Infect Dis 9;:1-9. MMWR ;9:1-9. CID ;3:-9. Updated May 1, From CLIN INFECT DIS (1): by the Infectious Diseases Society of America. All rights reserved. For permission to reuse, contact journalpermissions@press.uchicago.edu. Rifampin-Efavirenz Rifampin efavirenz AUC by % Consider efavirenz to mg qd CDC, NIH. MMWR ;3:RR-1 India: HIV+ patients with CD < All:EFV mg;1 (TB) also rifampin mg Same clinical, immunologic response Patel A et al. JAIDS ;37:11-9 Thailand: TB/HIV patients; mean weight kg EFV mg vs. mg: similar EFV levels and outcomes Manosuthi W. AIDS ;19:11-. South Africa: 19 TB/HIV EFV mg + rifampin mg EFV levels varied but good clinical outcomes Friedland G et al. JAC ;:199-3.
12 Rifampin-Nevirapine Rifampin lowers nevirapine levels by 37-% 3 small studies demonstrated favorable clinical and virologic response Ribera E JAIDS 1. Olivia J AIDS 3. Manosuthi CID. In a small study comparing mg NVP and mg EFV (both with rifampin), efficacy was similar but adverse events more common with NVP Manosuthi W. HIV Med ;9:9-9. At week 1, NVP levels more likely to be low than with EFV (1% vs. 3%; P=.) Manosuthi W. CID 9;:17-9. No clinical, pk, safety studies assessing increased nevirapine dose with rifampin Consider NVP + RIF when cannot use EFV, rifabutin not available, and close clinical and virologic monitoring can be performed Treatment of HIV-related TB Summary The clinical manifestations of TB in HIV-infected persons differ compared to HIV-uninfected persons Atypical or normal CXR Fewer symptoms Particularly with low CD; symptoms, CXR can worsen on ART Optimal treatment duration months enough? Daily dosing of TB therapy, particularly in first months Poor treatment outcomes associated with low PZA levels Acquired rifamycin resistance associated with low rifamycin levels, and perhaps low INH levels Advanced HIV, intermittent TB dosing also risk factors Acquired INH resistance not reported Failure to Suppress Viral Load in Patients With Concurrent TB at the Start of Antiretroviral Therapy vs Those Without Concurrent TB Boulle, A. et al. JAMA ;3:3-39. Copyright restrictions may apply. Treatment of TB/HIV New Agents Etravirine Rifampin etravirine do not give with rifampin Can give with rifabutin, but not together with DRV/r, SQV/r CCR inhibitors (maraviroc) Rifampin maraviroc C min by 7% in maraviroc dose to mg bid may help, but no clinical experience Interactions with rifabutin not studied; modest effect likely Integrase inhibitors (raltegravir) Rifampin raltegravir Cmax, AUC, trough levels by -71% Do not co-administer Can give RBT 3 mg qd with raltegravir mg bid Sterling TR. Clin Infect Dis 1;:S3-S3.
Non-rifampin rifamycins in TB/HIV
Non-rifampin rifamycins in TB/HIV Richard E. Chaisson, MD Johns Hopkins University Center for TB Research Consortium to Respond Effectively to the AIDS-TB Epidemic Rifamycins for TB Inhibit bacterial DNA-dependent
More informationApproach to Co-infection with TB and HIV: 2011 Henry Fraimow, MD
Approach to Co-infection with TB and HIV: 2011 Henry Fraimow, MD Consultant, Southern N.J. Regional Chest Clinic New Jersey State TB Physician Advisory Board Cooper Univ. Hospital EIP Program TB and HIV
More informationTB in the Patient with HIV
TB in the Patient with HIV Lisa Y. Armitige, MD, PhD May 11, 2017 TB Intensive May 9 12, 2017 San Antonio, TX EXCELLENCE EXPERTISE INNOVATION Lisa Y. Armitige, MD, PhD, has the following disclosures to
More informationHIV and TB coinfection: Updates. Awewura Kwara, MD, MPH &TM Associate Professor, Alpert Medical School of Brown University
HIV and TB coinfection: Updates Awewura Kwara, MD, MPH &TM Associate Professor, Alpert Medical School of Brown University Learning objectives Identify the optimal timing of antiretroviral therapy in patients
More informationTB Intensive Tyler, Texas December 2-4, Tuberculosis and HIV Co-Infection. Lisa Y. Armitige, MD, PhD. December 4, 2008.
TB Intensive Tyler, Texas December 2-4, 2008 Tuberculosis and HIV Co-Infection Lisa Y. Armitige, MD, Ph.D. December 4, 2008 Tuberculosis and HIV Co Infection Lisa Y. Armitige, MD, PhD Assistant Professor
More informationTB/HIV Co-Infection. Tuberculosis and HIV
TB Intensive Tyler, Texas June 2-4, 2010 TB/HIV Co-Infection Lisa Y Armitige, MD, PhD June 3, 2010 Tuberculosis and HIV Co-Infection Lisa Y Armitige, MD, PhD Medical Consultant Heartland National TB Center
More informationTB Intensive San Antonio, Texas May 7-10, 2013
TB Intensive San Antonio, Texas May 7-10, 2013 TB in the HIV Patient Lisa Armitige, MD, PhD May 09, 2013 Lisa Armitige, MD, PhD has the following disclosures to make: No conflict of interests No relevant
More informationTreatment of Tuberculosis, 2017
Treatment of Tuberculosis, 2017 Charles L. Daley, MD National Jewish Health University of Colorado Health Sciences Center Treatment of Tuberculosis Disclosures Advisory Board Horizon, Johnson and Johnson,
More informationDiagnosis and Treatment of Tuberculosis, 2011
Diagnosis of TB Diagnosis and Treatment of Tuberculosis, 2011 Alfred Lardizabal, MD NJMS Global Tuberculosis Institute Diagnosis of TB, 2011 Diagnosis follows Suspicion When should we Think TB? Who is
More informationTB Intensive San Antonio, Texas
TB Intensive San Antonio, Texas April 6-8, 2011 TB Disease: ATS/CDC/IDSA Guidelines Barbara Seaworth, MD Thursday April 7, 2011 Barbara Seaworth, MD has the following disclosures to make: Has received
More information8/28/2017. Learning Objectives. After attending this presentation, learners will be able to:
New and Noteworthy in Tuberculosis Diagnostics and Treatment Susan Swindells, MBBS Professor of Internal Medicine University of Nebraska Medical Center Omaha, Nebraska San Antonio, Texas: August 21 to
More informationTherapeutic Drug Monitoring for Improving TB Treatment Outcomes: A Concept for a Randomized Clinical Trial before Clinical Implementation
Therapeutic Drug Monitoring for Improving TB Treatment Outcomes: A Concept for a Randomized Clinical Trial before Clinical Implementation Randall Reves, MD, MSc TB Consultant Professor of Medicine and
More informationTB Intensive San Antonio, Texas. TB/HIV Co-Infection. Lisa Armitige, MD, PhD has the following disclosures to make:
TB Intensive San Antonio, Texas August 2-5, 2011 TB/HIV Co-Infection Lisa Armitige, MD, PhD August 4, 2011 Lisa Armitige, MD, PhD has the following disclosures to make: No conflict of interests No relevant
More informationPreventing TB: Recent Research Results and Novel Short Course Therapy for LTBI
Preventing TB: Recent Research Results and Novel Short Course Therapy for LTBI Constance A. Benson, M.D. Professor of Medicine Director, UCSD AntiViral Research Unit PI, CD4 Collaborative HIV Clinical
More informationTuberculosis Intensive November 17 20, 2015 San Antonio, TX
Treatment of Tuberculosis Elizabeth S. Guy, MD November 17, 2015 Tuberculosis Intensive November 17 20, 2015 San Antonio, TX EXCELLENCE EXPERTISE INNOVATION Elizabeth S. Guy, MD has the following disclosures
More informationTreatment of Tuberculosis
TB Intensive Tyler, Texas June 1-3, 2009 Treatment of Tuberculosis Barbara Seaworth, MD June 3, 2009 Treatment of Tuberculosis Barbara J Seaworth MD Medical Director Heartland National TB Center 1 Purpose
More informationTuberculosis Intensive
Tuberculosis Intensive San Antonio, Texas April 3 6, 2012 TB in the HIV Patient Lisa Armitige, MD, PhD April 6, 2012 Lisa Armitige, MD, PhD has the following disclosures to make: No conflict of interests
More informationTreatment of Tuberculosis
Treatment of Tuberculosis Marcos Burgos, MD April 5, 2016 TB Intensive April 5 8, 2016 San Antonio, TX EXCELLENCE EXPERTISE INNOVATION Marcos Burgos, MD has the following disclosures to make: No conflict
More informationErrors in Dx and Rx of TB
Errors in Dx and Rx of TB David Schlossberg, MD, FACP Professor of Medicine Temple University School of Medicine Medical Director, TB Control Program Philadelphia Department of Public Health TB Still a
More informationNEW DRUGS FOR TUBERCULOSIS: THE NEED, THE HOPE AND THE REALITY
NEW DRUGS FOR TUBERCULOSIS: THE NEED, THE HOPE AND THE REALITY Neil W. Schluger, M.D. Professor of Medicine, Epidemiology and Environmental Health Sciences Columbia University Global tuberculosis incidence
More informationMoving Past the Basics of Tuberculosis Phoenix, Arizona May 8-10, 2012
Moving Past the Basics of Tuberculosis Phoenix, Arizona May 8-10, 2012 LTBI and TB Disease Treatment Cara Christ, MD, MS May 8, 2012 Cara Christ, MD, MS has the following disclosures to make: No conflict
More informationPediatric Tuberculosis Lisa Y. Armitige, MD, PhD September 14, 2017
Pediatric Tuberculosis Lisa Y. Armitige, MD, PhD September 14, 2017 TB Nurse Case Management September 12 14, 2017 EXCELLENCE EXPERTISE INNOVATION Lisa Y. Armitige, MD, PhD has the following disclosures
More informationClinical Vignette: Patient 1. Approach to Co-infection with TB. TB and HIV Co-infection: Some Resources. Objectives.
TB and HIV Co-infection: Some Resources http://www.cdc.gov/tb AETC Natl Resource Center: http://www.aidsetc.org Approach to Co-infection with TB and HIV: 2012 Henry Fraimow, MD Consultant, Southern N.J.
More informationTB Prevention in PLHIV: Options Other Than Isoniazid. Johns Hopkins Center for Tuberculosis. Research. Richard E. Chaisson, MD
TB Prevention in PLHIV: Options Other Than Isoniazid Johns Hopkins Center for Tuberculosis Richard E. Chaisson, MD Research Johns Hopkins University Center for Tuberculosis Research Consortium to Respond
More informationCLINICAL VIGNETTE: Patient 1. Approach to Co-infection with TB and HIV: TB and HIV Co-infection: Some Resources. Goals and Objectives
TB and HIV Co-infection: Some Resources http://www.cdc.gov/tb http://www.umdnj.edu/globaltb/coretbresources.htm Approach to Co-infection with TB and HIV: 2011 Henry Fraimow, MD Consultant, Southern N.J.
More informationHIV/TB Co infection TB Clinical Intensive October 11, 2018
HIV/TB Co infection TB Clinical Intensive October 11, 2018 Gabriel Chamie, MD, MPH Associate Professor of Medicine Division of HIV, Infectious Diseases & Global Medicine UCSF/San Francisco General Hospital
More informationTuberculosis in AIDS Patients. Chien-Ching Hung Division of Infectious Diseases Department of Internal Medicine National Taiwan University Hospital
Tuberculosis in AIDS Patients Chien-Ching Hung Division of Infectious Diseases Department of Internal Medicine National Taiwan University Hospital Topics Epidemiology of TB in the era of HIV epidemic Impact
More informationImproving Translation in TB Drug Development Through Quantitative Modeling. CPTR Workshop 2016, Washington DC
Improving Translation in TB Drug Development Through Quantitative Modeling Lessons from Recent Phase III TB Trials CPTR Workshop 2016, Washington DC Christian Lienhardt Global TB Programme WHO, Geneva,
More information5. HIV-positive individuals treated with INH should receive Pyridoxine (B6) 25 mg daily or 50 mg twice/thrice weekly on the same schedule as INH
V. TB and HIV/AIDS A. Standards of Treatment and Management The majority of TB treatment principles apply to persons with HIV/AIDS who require treatment for TB disease. The following points are either
More informationTuberculosis and HIV
Julian Elliott National Centre in HIV Epidemiology and Clinical Research The University of New South Wales Epidemiology Diagnosis of TB Clinical management Does this woman have tuberculosis? Estimated
More informationWhat He Said: Rifampin versus Rifapentine
What He Said: Rifampin versus Rifapentine Charles A. Peloquin, Pharm.D. Director Infectious Disease Pharmacokinetics Laboratory Professor, College of Pharmacy & The Emerging Pathogens Institute University
More information1/18/2011. Handling TB and HIV. Fargo, North Dakota September 15-16, Treatment of TB in the HIV Co-Infected Patient
1/18/2011 Handling TB and HIV Co-Infection Fargo, North Dakota September 15-16, 2010 Treatment of TB in the HIV Co-Infected Patient Dean Tsukayama, MD September 15, 2010 1 Co-infection with TB and HIV
More informationACCESS TO MEDICINES. Update on tuberculosis field activities
ACCESS TO MEDICINES Update on tuberculosis field activities Update on clinical activities 1/3 Latent TB Prevent study (S26) main study (8053 patients) PK substudy construction of a POPPK model Paediatric
More informationCryptococcosis of the Central Nervous System: Classical and Immune-Reconstitution Disease
Cryptococcosis of the Central Nervous System: Classical and Immune-Reconstitution Disease Assist Prof. Somnuek Sungkanuparph Division of Infectious Diseases Faculty of Medicine Ramathibodi Hospital Mahidol
More informationTreatment of Tuberculosis
TB Clinical i l Intensive Seattle Treatment of Tuberculosis June 16, 2016 Masa Narita, MD Public Health Seattle & King County; Firland Northwest TB Center, University of Washington Outline Unique features
More informationDiagnosis and Medical Management of Latent TB Infection
Diagnosis and Medical Management of Latent TB Infection Marsha Majors, RN September 7, 2017 TB Contact Investigation 101 September 6 7, 2017 Little Rock, AR EXCELLENCE EXPERTISE INNOVATION Marsha Majors,
More informationHot Issues in Tuberculosis: Treatment of Latent TB Infection and New TB Drugs
Slide 1 Hot Issues in Tuberculosis: Treatment of Latent TB Infection and New TB Drugs Constance A. Benson, M.D. Professor of Medicine Division of Infectious Diseases University of California, San Diego
More informationTB/HIV CO-INFECTION ADULT & CHILDREN (INCLUDING INH PROPHYLAXIS) ART Treatment Guideline Training 31 st January to 4 th February, 2011
TB/HIV CO-INFECTION ADULT & CHILDREN (INCLUDING INH PROPHYLAXIS) ART Treatment Guideline Training 31 st January to 4 th February, 2011 OUTLINE Background Global Incidence The Problem" The 3 I s Drug Resistant
More informationHIV/TB. Sylvia LaCourse MD, MPH Department of Medicine, Division of Allergy & Infectious Disease. TB Clinical Intensive Seattle, WA June 16-17, 2016
HIV/TB Sylvia LaCourse MD, MPH Department of Medicine, Division of Allergy & Infectious Disease TB Clinical Intensive Seattle, WA June 16-17, 2016 Roadmap for today s talk HIV/TB Epidemiology Global US
More informationTuberculosis and HIV: key issues in diagnosis and management
Tuberculosis and HIV: key issues in diagnosis and management Julian Elliott Infectious Diseases Unit, Alfred Hospital Centre for Population Health, Burnet Institute julian.elliott@alfred.org.au Outline
More informationTuberculosis, HIV, and Corrections James B. McAuley, MD, MPH April 22, 2009
TB in the Correctional Setting Collinsville, Illinois April 22, 2009 Tuberculosis, HIV, and Corrections James B. McAuley, MD, MPH April 22, 2009 Tuberculosis, HIV, and Corrections James B. McAuley, MD
More informationTB Updates for the Physician Rochester, Minnesota June 19, 2009
TB Updates for the Physician Rochester, Minnesota June 19, 2009 Recent Findings & Activities of the Tuberculosis Trials Consortium (TBTC) Bill Burman Denver TBTC Unit & Denver Public Health Recent findings
More informationWeekly Moxifloxacin and Rifapentine Is More Active Than the Denver Regimen in Murine Tuberculosis
Weekly Moxifloxacin and Rifapentine Is More Active Than the Denver Regimen in Murine Tuberculosis Ian M. Rosenthal, Kathy Williams, Sandeep Tyagi, Andrew A. Vernon, Charles A. Peloquin, William R. Bishai,
More informationTB and Comorbidities Adriana Vasquez, MD April 12, 2018
TB and Comorbidities Adriana Vasquez, MD April 12, 2018 TB Nurse Case Management April 10 12, 2018 San Antonio, TX EXCELLENCE EXPERTISE INNOVATION Adriana Vasquez, MD has the following disclosures to make:
More informationHIV Infection Related Tuberculosis: Clinical Manifestations and Treatment
SUPPLEMENT ARTICLE HIV Infection Related Tuberculosis: Clinical Manifestations and Treatment Timothy R. Sterling, 1 Paul A. Pham, 2 and Richard E. Chaisson 2 1 Division of Infectious Diseases, Department
More informationGlobal epidemiology of drug-resistant tuberculosis. Factors contributing to the epidemic of MDR/XDR-TB. CHIANG Chen-Yuan MD, MPH, DrPhilos
Global epidemiology of drug-resistant tuberculosis Factors contributing to the epidemic of MDR/XDR-TB CHIANG Chen-Yuan MD, MPH, DrPhilos By the end of this presentation, participants would be able to describe
More informationTB/HIV management survey
TB/HIV management survey! Baseline audit in parallel with guidelines development process! Survey of clinician opinion and practice! Data collection from October 2004 to January 2005! Data was received
More informationTB Nurse Case Management San Antonio, Texas April 9-11, 2013
TB Nurse Case Management San Antonio, Texas April 9-11, 2013 TB / Dose Counting Rachel Munoz, RN. TB Nurse Case Manager/Nurse Consultant Austin/Travis County Health Department April 10, 2013 Rachel Munoz,
More informationTB & HIV CO-INFECTION IN CHILDREN. Reené Naidoo Paediatric Infectious Diseases Broadreach Healthcare 19 April 2012
TB & HIV CO-INFECTION IN CHILDREN Reené Naidoo Paediatric Infectious Diseases Broadreach Healthcare 19 April 2012 Introduction TB & HIV are two of the leading causes of morbidity & mortality in children
More informationMarcos Burgos, MD has the following disclosures to make:
Guidelines for the Treatment of Tuberculosis Marcos Burgos, MD May 13, 2015 TB for Pulmonologist March 13, 2015 Phoenix, AZ EXCELLENCE EXPERTISE INNOVATION Marcos Burgos, MD has the following disclosures
More informationTreatment of Active Tuberculosis
Treatment of Active Tuberculosis Jeremy Clain, MD Pulmonary & Critical Care Medicine Mayo Clinic October 16, 2017 2014 MFMER slide-1 Disclosures No relevant financial relationships No conflicts of interest
More informationCase Management of the TB/HIV Infected Patient
TB Nurse Case Management San Antonio, Texas December 8-10, 2009 Case Management of the TB/HIV Infected Patient Sarah Hoffman, MPH, MSN, ACRN December 9, 2009 TB/HIV: Considerations in the Care of the Coinfected
More informationTBTC research update: are we ready for 3 month treatment? 2009 TBTC Recompetition. NTCA presentation outline
TBTC research update: are we ready for 3 month treatment? Stefan Goldberg, MD Project officer, TBTC Studies 27, 28, 29 Tuberculosis Trials Consortium (TBTC) CDC Division of TB Elimination NTCA breakout
More informationImmune Reconstitution Inflammatory Syndrome. Dr. Lesego Mawela
Immune Reconstitution Inflammatory Syndrome Dr. Lesego Mawela TOPICS FOR DISCUSSION IRIS Case Epidermiology Pathogenesis of IRIS Risk factors for IRIS Epidemiology of IRIS Health system burden of IRIS
More informationActivity of PNU and its major metabolite in whole blood and broth culture models of TB
Activity of PNU 100480 and its major metabolite in whole blood and broth culture models of TB Paul Converse 1, Jin Lee 1, Kathy Williams 1, Opokua Amoabeng 1, Kim Dionne 1, Nicole Parish 1, Robert Wallis
More informationPharmacology and Pharmacokinetics of TB Drugs Part I
Pharmacology and Pharmacokinetics of TB Drugs Part I Charles A. Peloquin, Pharm. D. Professor, and Director Infectious Disease Pharmacokinetics Laboratory College of Pharmacy and The Emerging Pathogens
More informationPharmacokinetics (PK) and Pharmacodynamics (PD) in the Treatment of Tuberculosis
Pharmacokinetics (PK) and Pharmacodynamics (PD) in the Treatment of Tuberculosis Shaun E. Gleason, PharmD, MGS Associate Professor, Department of Clinical Pharmacy Director, Distance Degrees and Programs
More informationTB in the Correctional Setting Florence, Arizona October 7, 2014
TB in the Correctional Setting Florence, Arizona October 7, 2014 Diagnosis and Treatment of TB Disease Renuka Khurana, MBBS, MPH October 7, 2014 Renuka Khurana, MSSB, MPH has the following disclosures
More informationDiagnosis and Management of TB Disease Lisa Armitige, MD, PhD September 27, 2011
TB Nurse Case Management Davenport, Iowa September 27 28, 2011 Diagnosis and Management of TB Disease Lisa Armitige, MD, PhD September 27, 2011 Lisa Armitige, MD, PhD has the following disclosures to make:
More informationThe Role of Rifampin for the Treatment of Latent TB Infection. Introduction. Introduction
The Role of Rifampin for the Treatment of Latent TB Infection March 26, 2008 Alfred A. Lardizabal, MD Associate Professor of Medicine New Jersey Medical School Global Tuberculosis institute Treatment of
More informationSupplemental Digital Content 1. Combination antiretroviral therapy regimens utilized in each study
Supplemental Digital Content 1. Combination antiretroviral therapy regimens utilized in each study Study Almeida 2011 Auld 2011 Bassett 2012 Bastard 2012 Boulle 2008 (a) Boulle 2008 (b) Boulle 2010 Breen
More informationTuberculosis: update 2013
Tuberculosis: update 2013 William R. Bishai, MD, PhD Center for TB Research Division of Infectious Diseases Department of Medicine Johns Hopkins School of Medicine Question 1 A TB speaker at a major conference
More informationDiagnosis & Medical Case Management of TB Disease. Lisa Armitige, MD, PhD October 22, 2015
Diagnosis & Medical Case Management of TB Disease Lisa Armitige, MD, PhD October 22, 2015 Comprehensive Care of Patients with Tuberculosis and Their Contacts October 19 22, 2015 Wichita, KS EXCELLENCE
More informationWhat more is required to use rifamycin regimens to prevent TB in people living with HIV in resource constrained settings?
What more is required to use rifamycin regimens to prevent TB in people living with HIV in resource constrained settings? Gary Maartens Division of Clinical Pharmacology UNIVERSITY OF CAPE TOWN IYUNIVESITHI
More informationCo-morbidities that Impact Managing TB Lisa Armitige, MD, PhD November 17, 2010
Substance Abuse and Tuberculosis Oklahoma City, Oklahoma November 17, 2010 Co-morbidities that Impact Managing TB Lisa Armitige, MD, PhD November 17, 2010 Co-morbidities in Substance Abuse that Impact
More informationOutline. A 41 Year-old Male COMMON PITFALLS IN HIV/AIDS MANAGEMENT: A CASE-BASED APPROACH. Q1: What anti-fungal regimen would you start?
Outline COMMON PITFALLS IN HIV/AIDS MANAGEMENT: A CASE-BASED APPROACH Considerations for antiretroviral use in patients with coinfections Concerning and how to manage drug-drug interactions ARV-other drugs
More informationEvidence review for Intermittent therapy for drug-susceptible TB: Questions addressed: intermittent therapy
Evidence review for Intermittent therapy for drug-susceptible TB: Dr. Dick Menzies Montreal Chest Institute, McGill University Montreal, Canada Questions addressed: intermittent therapy 1: Does intermittent
More informationNurse Case Management Phoenix, Arizona February 20-22, 2008
Nurse Case Management Phoenix, Arizona February 20-22, 2008 TB/HIV: Managing the Co-Infected Patient Adriana Vasquez, MD February 21, 2008 HIV Treatment Guidelines DHHS December 1,2007 TB/HIV Managing
More informationTreatment of Tuberculosis
Treatment of Tuberculosis, 1940 s Treatment of Tuberculosis ATS/CDC/IDSA Joint Statement 2003 Saskatchewan Lung Association Outline, 2012 Treatment of Tuberculosis Principles of treatment of tuberculosis
More informationTuberculosis Tools: A Clinical Update
Tuberculosis Tools: A Clinical Update CAPA Conference 2014 JoAnn Deasy, PA-C. MPH, DFAAPA jadeasy@sbcglobal.net Adjunct Faculty Touro PA Program Learning Objectives Outline the pathogenesis of active pulmonary
More informationCLINICAL DIAGNOSIS AND MANAGEMENT OF TB Disease
CLINICAL DIAGNOSIS AND MANAGEMENT OF TB Disease Barbara J Seaworth MD Medical Director Heartland National TB Center Professor of Medicine University of Texas Health Center Tyler Barbara J Seaworth MD has
More informationThe role of ART and IPT in TB prevention: Latest updates
The role of ART and IPT in TB prevention: Latest updates Richard E. Chaisson, MD Center for Tuberculosis Research Johns Hopkins University Consortium to Respond Effectively To the AIDS-TB Epidemic (CREATE)
More informationTB Expert Network Conference 9/26/2008
TB Expert Network Conference 9/26/2008 Case 1-KT1 35 y/o AA male with a history of HIV since 2002. Presented in July 2007 to a hospital in Orlando, FL with 1 month history of productive cough, fevers and
More informationRecognizing MDR-TB in Children. Ma. Cecilia G. Ama, MD 23 rd PIDSP Annual Convention February 2016
Recognizing MDR-TB in Children Ma. Cecilia G. Ama, MD 23 rd PIDSP Annual Convention 17-18 February 2016 Objectives Review the definitions and categorization of drugresistant tuberculosis Understand the
More informationContact Investigation and Prevention in the USA
Contact Investigation and Prevention in the USA George D. McSherry, MD Division of Infectious Disease Penn State Children s Hospital Pediatric Section TB Center of Excellence Rutgers Global Tuberculosis
More informationTUBERCULOSIS. Pathogenesis and Transmission
TUBERCULOSIS Pathogenesis and Transmission TUBERCULOSIS Pathogenesis and Transmission Infection to Disease Diagnostic & Isolation Updates Treatment Updates Pathogenesis Droplet nuclei of 5µm or less are
More informationPrinciples and practice of treating drug-sensitive TB
Principles and practice of treating drug-sensitive TB Brian Eley Paediatric Infectious Diseases Unit Red Cross War Memorial Children s Hospital Department of Paediatrics and Child Health University of
More informationDrug Interactions Lisa Armitige, MD, PhD November 17, 2010
Substance Abuse and Tuberculosis Oklahoma City, Oklahoma November 17, 2010 Drug Interactions Lisa Armitige, MD, PhD November 17, 2010 Drug Interactions Lisa Y. Armitige, M.D., Ph.D. Medical Consultant
More informationDIAGNOSIS AND MEDICAL MANAGEMENT OF TB DISEASE
DIAGNOSIS AND MEDICAL MANAGEMENT OF TB DISEASE Annie Kizilbash MD, MPH Assistant Professor University of Texas Health Science Center Staff Physician, Texas Center for Infectious Diseases TB Nurse Case
More informationSA TB Guidelines The interface with Advanced Clinical Care
SA TB Guidelines The interface with Advanced Clinical Care Dr Kogie Naidoo (MBCHB, PHD) Head: CAPRISA Treatment Research Programme Honorary Lecturer - UKZN Department of Public Heath Medicine Annual Workshop
More informationHIV Treatment Update. Awewura Kwara, MD, MPH&TM Associate Professor of Medicine and Infectious Diseases Brown University
HIV Treatment Update Awewura Kwara, MD, MPH&TM Associate Professor of Medicine and Infectious Diseases Brown University Outline Rationale for highly active antiretroviral therapy (HAART) When to start
More informationTreatment of Latent TB Infection (LTBI)
Treatment of Latent TB Infection (LTBI) Mahesh C. Patel, MD June 14, 2017 2014 MFMER slide-1 Mahesh C. Patel, MD Associate Professor Treatment of LTBI Department of Internal Medicine, Division of Infectious
More informationOutline 8/2/2013. PK/PD PK/PD first-line drug กก PK/PD กก
Pharmacokinetic and pharmacodynamic of anti- tuberculosis drugs Outline PK/PD PK/PD first-line drug กก PK/PD กก Concentration vs time in tissue and other body fluids Pharmacologic or toxicologic effect
More informationESCMID Online Lecture Library. by author
Tuberculosis prevention in immunodepressed patients M. Carmen Fariñas Álvarez Infectious Diseases.H.U.Marqués de Valdecilla University of Cantabria, Spain DISCLOSURES I have no potential conflicts with
More information6/8/2018 TB TREATMENT. Bijan Ghassemieh, MD Seattle TB Clinical Intensive Disclosures. None
TB TREATMENT Bijan Ghassemieh, MD Seattle TB Clinical Intensive 2018 Disclosures None 1 Objectives Understand the following Rationale and goals for standard TB regimen When to initiate TB treatment Standard
More informationWhat is drug resistance? Musings of a clinician
What is drug resistance? Musings of a clinician William Burman MD Denver Public Health Tuberculosis Trials Consortium Financial disclosures Tibotec (developer of TMC207 and several antiretroviral drugs)
More informationPZA: A New Look Based on RNASeq, the Hollow Fiber System, and Patient Level Data. Tawanda Gumbo
PZA: A New Look Based on RNASeq, the Hollow Fiber System, and Patient Level Data Tawanda Gumbo Office of Global Health University of Texas Southwestern Medical Center, Dallas, Texas The team: this work
More informationPrinciples of Antiretroviral Therapy
Principles of Antiretroviral Therapy Ten Principles of Antiretroviral Therapy Skills Building Workshop: Clinical Management of HIV Infection and Antiretroviral Therapy, 11 th ICAAP, November 21st, 2011,
More informationTB in Prisons and Jails Albuquerque, New Mexico November 28, 2012
TB in Prisons and Jails Albuquerque, New Mexico November 28, 2012 Challenges of TB Treatment in Special Populations in Corrections Marcos Burgos, MD November 28, 2012 Marcos Burgos, MD has the following
More informationEfavirenz vs dolutegravir for 1st line ART: Is it time to change? The argument AGAINST. Graeme Meintjes University of Cape Town
Efavirenz vs dolutegravir for 1st line ART: Is it time to change? The argument AGAINST Graeme Meintjes University of Cape Town Benefits of dolutegravir Superior efficacy in SINGLE trial Side effect profile
More informationhas the following disclosures to make:
CLINICAL DIAGNOSIS AND MANAGEMENT OF TB DISEASE Annie Kizilbash MD, MPH September 22, 2015 TB Nurse Case Management September 22 24, 2015 San Antonio. TX EXCELLENCE EXPERTISE INNOVATION Annie Kizilbash
More informationRajesh T. Gandhi, M.D.
HIV Treatment Guidelines: 2010 Rajesh T. Gandhi, M.D. Case 29 yo M with 8 weeks of cough and fever. Diagnosed with smear-positive pulmonary TB. HIV-1 antibody positive. CD4 count 361. HIV-1 RNA 23,000
More informationMycobacterial Infections: What the Primary Provider Should Know about Tuberculosis
Mycobacterial Infections: What the Primary Provider Should Know about Tuberculosis Henry F. Chambers, M.D Professor of Medicine, UCSF Topics for Discussion Epidemiology Diagnosis of active TB Screening
More informationTuberculosis and Diabetes Dec. 10, 2009 Dean Schillinger, M.D. and Gisela Schecter, M.D., M.P.H. 1 of 18
Screening, Diagnosis, and Treatment of TB in Persons with Diabetes Dean Schillinger, M.D. University of California San Francisco CA Diabetes Program Gisela Schecter, M.D., M.P.H. TB Control Branch CA Department
More informationTreatment experience in South Africa. Dr Ian Sanne Clinical HIV Research Unit University of the Witwatersrand
Treatment experience in South Africa Dr Ian Sanne Clinical HIV Research Unit University of the Witwatersrand Overview South African Prevalence Adherence Combination ddi + d4t Nevirapine Hepatotoxicity
More informationPotent Twice-Weekly Rifapentine-containing Regimens in Murine Tuberculosis
Potent Twice-Weekly Rifapentine-containing Regimens in Murine Tuberculosis Ian M. Rosenthal, Kathy Williams, Sandeep Tyagi, Charles A. Peloquin, Andrew A. Vernon, William R. Bishai, Jacques H. Grosset,
More informationTB Intensive Houston, Texas. Childhood Tuberculosis Kim Connelly Smith. November 12, 2009
TB Intensive Houston, Texas November 10-12, 12 2009 Childhood Tuberculosis Kim Connelly Smith MD, MPH November 12, 2009 Childhood Tuberculosis Kim Connelly Smith MD, MPH November 12, 2009 1 OUTLINE Stages
More informationDrug Interactions with ART and New TB drugs: What Do We Know?
Drug Interactions with ART and New TB drugs: What Do We Know? HIV/TB Research Frontiers Meeting 20 th Conference on Retroviruses and Opportunistic Infections 3 March 2013 Presented by: Kelly Dooley MD,
More informationTB and Co-Morbidities Lisa Armitige, MD, PhD September 27, 2011
TB Nurse Case Management Davenport, Iowa September 27 28, 2011 TB and Co-Morbidities Lisa Armitige, MD, PhD September 27, 2011 Lisa Armitige, MD, PhD has the following disclosures to make: No conflict
More informationPatient History 1. Patient History 2. Social History. The Role of Surgery in the Management of TB. Reynard McDonald, MD & Paul Bolanowski, MD
Patient History 1 The Role of Surgery in the Management of TB Reynard McDonald, MD & Paul Bolanowski, MD September 16, 2010 42 y/o AA male was initially diagnosed with pansensitive pulmonary TB in 1986
More information